Sex steroids and breast density predict breast cancer risk

Article

Both circulating sex steroid levels and mammographic density are strong and independent predictors of breast Ca risk in postmenopausal women. . .

Both circulating sex steroid levels and mammographic density are strong and independent predictors of breast cancer risk in postmenopausal women, according to the results of a nested case-control study.

Using a cohort of 253 women with breast cancer and 520 controls within the Nurses' Health Study, researchers found that women in the highest quartile for mammographic density had almost four times the risk for breast cancer as women in the lowest quartile (RR 3.8; 95% CI, 2.2–6.6; Ptrend<0.001). Adjusting the analysis for circulating estradiol or circulating testosterone made little change (RR 3.9; 95% CI, 2.2–6.0; Ptrend<0.001; and RR 4.1; 95% CI, 2.3–7.2, Ptrend<0.001, respectively). Women with high levels of circulating estradiol or circulating testosterone had about twice as high a risk for developing breast cancer as women with low levels, before and after adjustment for mammographic density (RR 2.4; 95% CI, 1.4–4.0; and RR 2.0; 95% CI, 1.2–3.1, respectively). Women who had both high levels of plasma testosterone and very dense breasts were at six times the risk for breast cancer as women in the lowest tertiles for both (RR 6.0; 95% CI, 2.6–14.0). Figures were similar for women with both high circulating estradiol and mammographic density (RR 4.1; 95% CI, 1.7–9.8).

Tamimi RM, Byrne C, Colditz GA, et al. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2007;99:1178-1187.

Recent Videos
HPV self-collection: Benefits, limitations, and future implications | Image Credit: forhers.com
Improving pediatric HPV vaccination rates: Early initiation and addressing disparities | Image Credit: blog.nemours.org.
New cervical cancer screening guidelines: What practitioners needs to know | Image Credit: forhers.com
COVID-19 Therapy Roundtable: Focusing on inpatient care
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
How fezolinetant advances non-hormonal treatment of hot flashes | Image Credit: medschool.cuanschutz.edu
Contraceptive access challenges for college students in contraception deserts | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.